There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic out...
Background: Psilocybin therapy (PT) produces rapid and persistent antidepressant effects in major depressive disorder (MDD). However, the long-term effects of PT have never been compared with gold-standard treatments for MDD such as pharmacotherapy or psychotherapy alone or in combination. Methods: This is a 6-month follow-up study of a phase 2, double-blind...
This study aims to estimate the lower, middle, and upper bounds of potential demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant depression (TRD) in the United States. We calculated potential PSIL-AT demand for MDD and TRD by estimating the number of U.S. patients with MDD, identifying those in treatme...
Abstract Background and Aims This naturalistic mixed methods field study, aimed to assess the potential of a psilocybin induced experience, to help Emergency Medical Service Workers (EMSW) to address psychological and stress related symptoms stemming from a challenging working environment, known to contribute to occupational burnout (OB). Methods This explor...
Psilosibin, klasik bir serotonerjik psikedelik madde olup, depresyon, anksiyete, travma sonrası stres bozukluğu, obsesif kompulsif bozukluk, yeme bozuklukları ve bağımlılık gibi ruhsal bozuklukların tedavisinde umut vaat etmektedir. Bu derleme, mevcut literatürü analiz ederek, psilosibinin terapötik etkilerini, olası mekanizmalarını ve klinik kullanımına dai...
Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional treatments. One potential solution being explored is psilocybin assisted psychotherapy (PAP) which shows promise for treating depression. A recent study by Rosenblat et al. explores the use of psilocybin in clinical...
This article discusses evidence that offers insights into the effects of psilocybin on the brain and its potential role in alleviating the symptoms of some neuropsychiatric conditions.
Cancer patients are more vulnerable to developing psychiatric disorders like anxiety and depression. These conditions give an additional burden leading to poor quality of life. The available antidepressant and antianxiety drugs are not very useful in improving quality of life by reducing anxiety and depressive episodes. Therefore, there is a need for good dr...
RATIONALE: Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (TRD). Focusing on Wistar-Kyoto (WKY) rats with a TRD phenotype and Wistar (WIS) rats as a normative comparison, we investigated behavioral and neuroplasticity-related responses to PSI, striving to shed l...
BACKGROUND: Major depressive disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phas...
Many medicines and treatments for varying levels of ailments were found through natural bioactives before complex separation techniques were available.Ironically, as medicine advances, drastically more people seem to be reverting to a desire for these natural bioactives.Due to this, it is important to discover and research the pharmacology of historically us...
Introduction: Mental disorders are common and still growing problem around the globe. Significantly decreasing quality of life, they are often source of true suffering for patients and their families leading to further health issues or even dramatic outcomes resulting in death. As public awareness rises, more and more people understand risks and tend to look...
The journal and the authors are investigating the problem.The study analysed data from randomised trials of psilocybin for the treatment of depression in adults.A methodological concern has been raised about an error in the calculation of standardised mean differences.This is likely to have overestimated the benefits of psilocybin.The authors are reviewing a...
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and MoreTerri D'ArrigoTerri D'ArrigoPublished Online:23 Apr 2024https://doi.org/10.1176/appi.pn.2024.05.5.1Vanda Gets Yes for Iloperidone for Bipolar, No for InsomniaVanda Pharmaceuticals Inc. announced in April th...
Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexi...
To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.
